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Article abstract—Axonal damage probably occurs early in the evolution of
MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3
protein in the CSF obtained at the first clinically isolated syndrome sugges-
tive of MS. A positive 14-3-3 assay was the only independent predictor for a
shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to
15) and to reach an Expanded Disability Status Scale (EDSS) 2 at the end
of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8). The detection of the 14-3-3
protein in the CSF at the first neurologic event suggestive of MS may be a
useful predictor of short-term evolution.
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In a given patient with a first clinically isolated syn-
drome suggestive of MS, the prediction of the clinical
evolution remains a challenge. Brain MRI and CSF
oligoclonal IgG bands are helpful to identify which
patients are at risk of developing clinically definite
MS (CDMS).1 However, how soon patients will have
a second relapse or which patients will have early
functional impairment cannot be predicted with
accuracy.
Axonal damage is recognized as part of the MS
lesion and probably occurs early in the evolution of
the disease.2 We hypothesized that patients at risk of
early disability or with higher relapse rate could be
those with more prominent or persistent axonal
damage at the onset of MS. At present, there are no
biologic markers of axonal damage in MS. In this
study, we analyzed whether the detection of 14-3-3
protein and S100 in the CSF obtained at the first
clinically isolated syndrome suggestive of MS might
serve as markers of early axonal injury and predic-
tors of the clinical outcome of these patients. Both
proteins are increased in the CSF of neurologic disor-
ders associated with subacute, usually severe, neuro-
nal damage.3-6
Patients and methods. We retrospectively analyzed
the presence of 14-3-3 and S100 in the CSF of 38 patients
obtained within 30 days of a first clinically isolated syn-
drome suggestive of MS as part of the diagnostic workup.
Patients were followed in the MS units of the two partici-
pating hospitals and did not receive any specific treatment
except steroids during relapses. A relapse was defined as
the occurrence of new neurologic symptoms or the worsen-
ing of previous symptoms that lasted more than 24 hours
and that stabilized or resolved either partially or com-
pletely. CSF samples were kept frozen at 80 °C until the
time of analysis. The baseline characteristics of the pa-
tients are summarized in table 1.
The presence of 14–3-3 protein was analyzed by immu-
noblot using an anti–14-3-3 antibody reactive against all
isoforms (no. Sc-629; Santa Cruz Biotechnology, Santa
Cruz, CA) as previously described.3 S100 was measured
by an immunoluminometric method following the manu-
facturer’s guidelines (LIA-mat Sangtec 100, Bromma, Swe-
den). CSF analysis was done blind to clinical, MRI, or
CSF results in the same laboratory (Hospital Clinic).
Statistical analysis. Mann–Whitney exact-rank test
for quantitative noncontinuous variables, Student’s t-test
for continuous variables and 2 test for categorical vari-
ables were used to study differences between the 14-3-3–
positive and –negative groups. The time to the second
relapse in both groups was compared using log-rank test.
Cox proportional hazards regression model was used to
verify associations between time to present a second neu-
rologic event suggestive of MS (CDMS) and the following
variables: age; sex; hospital; Kurtzke’s Expanded Disabil-
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ity Status Scale (EDSS) score at the time of the first event;
MRI suggestive of MS (four supratentorial lesions or three
lesions with at least one of infratentorial location or en-
hanced with gadolinium); presence of oligoclonal IgG
bands, IgG index 0.7, albumin index 9.0, or pleocytosis
in CSF; the use of corticosteroids in the first relapse; the
results of the 14-3-3 assay; and the S100 and IgG levels
in the CSF. A multivariate logistic regression was per-
formed including the same variables to ascertain possible
predictors for an EDSS 2 (evidence of at least mild dis-
ability) at the end of the follow-up.
Results. The 14-3-3 assay was positive in five patients
(13.2%). There were no differences between 14-3-3–positive
or –negative patients in age; sex; EDSS at onset; abnormal
MRI; presence of oligoclonal IgG bands, elevated IgG in-
dex, elevated albumin index, or pleocytosis in CSF; and
mean time of follow-up. The S100 levels were higher in
the CSF of the 14-3-3–positive patients (table 2). The mean
(
 SD) decrease of the EDSS score shortly after the re-
lapse, as a measure of recovery, was 0.8 (1.05) for the
14-3-3–positive group compared with 1.6 (1.8) for the 14-3-
3–negative patients (p  0.02).
At the end of the follow-up, 80% of the 14-3-3–positive
Table 1 Baseline characteristics of the 38 patients with a first
clinically isolated syndrome suggestive of MS
Characteristics Value
Median age, y, (range) 32 (18–52)
Women, n (%) 25 (66)
Clinical syndrome
Spinal cord 14 (38.2)
Optic neuritis 9 (23.5)
Brainstem 8 (20.6)
Supratentorial/other 7 (17.7)
EDSS, median (range) 3.0 (1.0–5.5)
MRI suggestive of MS, n (%)* 30 (79)
CSF OB or IgG index 0.7, n (%) 28 (73.7)
Steroid treatment at first relapse, n (%) 32 (84.6)
Median follow-up, mo, (range) 27.3 (6–68)
* MRI suggestive of MS demonstrates four supratentorial lesions
or three lesions, at least one infratentorial or gadolinium en-
hancing.
EDSS  Expanded Disability Status Scale, CSF OB  oligo-
clonal IgG bands.
Table 2 Association between baseline and outcome characteristics and the presence of 14-3-3 protein in the CSF
Characteristics
14-3-3 in CSF
p ValueYes (n  5) No (n  33)
Median age, y (range) 34.1 (29–39) 31 (18–52) NS
Women, n (%) 5 (100) 20 (60) NS
EDSS at first event, median (range) 3.0 (2.0–4.0) 3.0 (1.0–5.5) NS
MRI suggestive of MS, n (%)* 4 (80) 26 (79.7) NS
CSF OB/IgG index 0.7, n (%) 5 (100) 23 (69.7) NS
CSF pleocytosis, 	15 cells/L 0 (0) 3 (9) NS
Albumin index 9.0† 0 (0) 2 (6) NS
S100, g/L, mean 
 SD 1.4 
 0.82 0.9 
 0.38 0.04
Median time of follow-up, mo (range) 36 (7–39) 27 (6–68) NS
Conversion to CDMS, n (%) 4 (80) 19 (57.5) NS
Median time to second relapse, mo 5.4 23.4 0.01
No. of relapses, mean 
 SD 3.6 
 2.0 2.0 
 1.3 0.03
EDSS 2 at the end of follow-up, n (%) 4 (80) 7 (22) 0.02
* MRI suggestive of MS demonstrates four supratentorial lesions or three lesions, at least one infratentorial or gadolinium enhancing.
† Albumin index 9.0 indicates disruption of the blood–brain barrier.
CSF OB  oligoclonal IgG bands; CDMS  clinically definite MS; EDSS  Expanded Disability Status Scale.
Figure. Kaplan–Meier method shows the probability of no
conversion to clinically definite MS in function of positive
(solid line) or negative (broken line) 14-3-3 protein in CSF.
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and 57.5% of the 14-3-3–negative patients developed
CDMS. Compared with the 14-3-3–negative group, the 14-
3-3–positive patients had a shorter time to conversion to
CDMS (5.4 vs 23.4 months; p  0.012) (figure), a higher
relapse rate (3.6 vs 2.0; p  0.03), and a higher frequency
of patients with EDSS 2 at the end of the study (80% vs
22%; p  0.02) (see table 2).
In the multivariate analysis, the detection of the 14-3-3
protein in the CSF was the only variable associated with a
shorter time to develop CDMS (risk ratio 4.1; 95% CI 1.1 to
15). Similarly, the presence of 14-3-3 protein in the CSF
was an independent predictive factor for achieving an
EDSS score 2 at the end of the follow-up (odds ratio 14.8;
95% CI 2.86 to 76.8).
Discussion. Our study shows that 13% of patients
presented 14-3-3 protein in the CSF obtained at the
first neurologic event suggestive of MS. The positive
assay was associated with a shorter time to conver-
sion to CDMS, a higher relapse rate, and an in-
creased disability at the end of the follow-up.
The high proportion of patients who developed
CDMS in our study (60%) agrees with the frequency
of MRI that are suggestive of MS at the first event.
Patients with an abnormal MRI at the time of pre-
sentation with a clinically isolated syndrome have a
increased risk of developing CDMS over the next 5
years.1 However, neither the MRI or presence of CSF
oligoclonal IgG bands is a good predictive marker of
early relapse or severity of neurologic dysfunction
among those patients who develop MS.
Natural history studies of MS have identified
early clinical and MRI variables that, when taken
together, may predict the short-term outcome of a
given patient and, with less accuracy, the long-term
evolution. However, these predictors included, in ad-
dition to baseline characteristics such as age, clinical
syndrome, and MRI status, variables such as fre-
quency of relapses, interval between first two re-
lapses, and recovery from initial attacks.7 Our study
also suggests that there is not a single clinical vari-
able that predicts the clinical outcome, but we iden-
tified a CSF 14-3-3–positive assay as an independent
prognostic factor for early relapse and disability in
the short term.
The 14-3-3 family protein is expressed in the cell
body and processes of neurons and may be detected
in the CSF of patients with some neurologic disor-
ders that cause subacute damage of the nervous sys-
tem.3,4 The detection of 14-3-3 protein in the CSF of
patients with a first neurologic event suggestive of
MS may reflect early neuronal injury. The correla-
tion of the positive 14-3-3 assay with increased levels
of S100 in the CSF6 further supports this hypothe-
sis. Although S100 is an astroglial marker, both
proteins can be detected in conditions associated
with neural damage. However, in our study, the only
predictor of the clinical course was the 14-3-3 pro-
tein, as demonstrated by the multivariate analysis.
The 14-3-3 protein was analyzed in seven patients
with transverse myelitis of different origins and was
detected in the CSF of the four patients who showed
little or no recovery from their acute illness.5 In our
study, the presence of 14-3-3 protein in the CSF was
not associated with the EDSS score during the first
neurologic event but confirmed the correlation with a
worse recovery. Moreover, the association between a
positive CSF 14-3-3 assay and disability at the end of
the follow-up would suggest that there is sustained
axonal damage in absence of clinical activity. Be-
cause in the present study the lumbar puncture was
only performed at the first neurologic event, we do
not have evolutionary data supporting this hypothe-
sis. However, this possibility is supported by recent
data on brain atrophy in the follow-up of patients at
risk of MS. A significant increase in ventricular size
during the first year after the first neurologic event
was only observed in those patients who developed
CDMS compared with those who had no further
symptoms.8
Recent studies demonstrated that early treatment
with interferon beta delays the conversion to CDMS
in patients with a first relapse suggestive of MS.9,10
We realize this is a small series, but if the results are
confirmed in larger studies, the 14-3-3 assay could be
included in the decision-making algorithms to define
patients who may benefit from early treatment at
the time of the first relapse.
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